All peptides discussed in this guide are sold by Webber Science for in vitro research purposes only.
Introduction
SLU-PP-332 is an emerging research peptide classified as an exercise mimetic — a compound that activates some of the same metabolic pathways triggered by physical exercise. Specifically, it functions as a potent agonist of estrogen-related receptor alpha (ERRα), a nuclear receptor that regulates mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation.
For Canadian research labs studying metabolic optimization, mitochondrial function, and exercise physiology at the molecular level, SLU-PP-332 represents an intriguing tool for pathway dissection.
Mechanism of Action
SLU-PP-332 acts through ERRα (estrogen-related receptor alpha), which is distinct from classical estrogen receptors:
1. ERRα activation — Binds and activates ERRα, a nuclear receptor that functions as a master regulator of mitochondrial gene expression
2. PGC-1α synergy — ERRα works in concert with PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the same coactivator induced by exercise
3. Mitochondrial biogenesis — Upregulates genes encoding oxidative phosphorylation complexes, fatty acid oxidation enzymes, and mitochondrial transcription factors
4. Fatty acid oxidation — Increases expression of CPT1, MCAD, and LCAD — key enzymes in mitochondrial fatty acid metabolism
5. Type I muscle fiber shift — Promotes slow-twitch (type I) fiber gene expression, mirroring exercise adaptation
The key insight: SLU-PP-332 doesn’t just stimulate one pathway — it activates the entire ERRα-mediated transcriptional program that naturally activates during endurance exercise.
Research Evidence
Original Publication (SLU-PP Series)
The SLU-PP compound series was developed at Saint Louis University (hence SLU-PP), with key findings published in peer-reviewed literature:
- Exercise gene signature activation — SLU-PP-332 activated 85–90% of exercise-upregulated genes in murine skeletal muscle cell models
- Endurance capacity — Treated mice showed significantly increased running endurance in treadmill tests without prior exercise training
- Mitochondrial content — Mitochondrial DNA copy number and citrate synthase activity increased in treated vs. control groups
- Fatty acid oxidation — Measured via palmitate oxidation assays; SLU-PP-332 treated cells showed 30–50% increase in oxidation rate
- Body composition — Reduced visceral fat accumulation in high-fat diet rodent models versus controls
Comparison with Exercise
SLU-PP-332 recapitulates approximately 80–90% of the exercise-induced ERRα gene signature but does not fully replicate all exercise effects (mechanical stress, cardiovascular adaptation, CNS effects). It is best characterized as a metabolic exercise mimetic rather than a complete exercise substitute.
Research Protocol Considerations
In Vitro Study Design
- Cell models: C2C12 myotubes (mouse), primary human skeletal muscle cells
- Readouts: Oxygen consumption rate (Seahorse/Agilent), fatty acid oxidation, mitochondrial DNA copy number, ERRα target gene expression (qPCR)
- Concentration range: Start with 1–10 μM in cell culture; dose-response recommended
- Duration: Gene expression changes observable at 24–48 hours; mitochondrial biogenesis markers at 48–72 hours
In Vivo Considerations
- Route: Intraperitoneal injection in rodent models; subcutaneous in research contexts
- Duration: Published studies used 2–4 week treatment periods
- Endpoints: Treadmill endurance, VO2max, mitochondrial content, body composition (DEXA), glucose tolerance
Reconstitution and Handling
- Reconstitution: Use bacteriostatic water or appropriate research-grade vehicle
- Use our peptide calculator for reconstitution calculations
- Storage: Lyophilized at -20°C; protect from light
- Stability: Reconstituted solutions should be used within 2–3 weeks when refrigerated
SLU-PP-332 vs Other Metabolic Peptides
| Feature | SLU-PP-332 | AOD9604 | MOTS-c | Retatrutide |
|———|———–|———|——–|————-|
| Primary target | ERRα | β3-AR (HGH fragment) | AMPK | GLP-1R/GIPR/GCGR |
| Mechanism | Exercise mimetic | Lipolysis | Mitochondrial peptide | Triple incretin |
| Exercise gene activation | ~85–90% | Minimal | Partial | Minimal |
| Mitochondrial biogenesis | Strong | Minimal | Moderate | Minimal |
| Fatty acid oxidation | Strong | Moderate | Moderate | Strong (indirect) |
| Clinical evidence | Preclinical only | Phase 2 (completed) | Preclinical | Phase 3 (ongoing) |
Frequently Asked Questions
Is SLU-PP-332 the same as exercise?
No. SLU-PP-332 activates approximately 85–90% of the ERRα-mediated exercise gene signature but does not replicate mechanical stress, cardiovascular hemodynamics, or CNS exercise adaptations. It is a metabolic exercise mimetic — a research tool for studying exercise pathways, not an exercise replacement.
Why is it called an “exercise mimetic” rather than just a metabolic peptide?
Because its primary mechanism (ERRα activation) is the same nuclear receptor pathway that endurance exercise activates. The term “exercise mimetic” is mechanistically accurate — it mimics the ERRα-dependent component of exercise adaptation.
Can SLU-PP-332 be combined with other peptides?
Theoretically, combining SLU-PP-332 (ERRα) with MOTS-c (AMPK) or retatrutide (incretin) addresses complementary pathways. However, single-variable research designs are recommended before exploring combinations. See our peptide blends methodology guide.
What’s the research status of SLU-PP-332?
SLU-PP-332 is in the preclinical research phase. Published data includes cell culture studies, murine endurance and metabolic models, and gene expression profiling. No human clinical trials have been conducted to date.
Related Research Guides
Disclaimer: SLU-PP-332 is provided by Webber Science for in vitro research purposes only. Not intended for human consumption, diagnosis, or treatment of any medical condition.